Tivicay
indicated for human immunodeficiency virus infection to alleviate viral load.
Strengths: 50mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Integrase Strand Transfer Inhibitor (INSTI)
- Pharmacological class
Integrase Inhibitor
- Contraindications
hypersensitivity to dolutegravir; concurrent use of dofetilide
- Minor side effects
insomnia; headache; fatigue; nausea
- Moderate side effects
elevated liver enzymes; rash
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
indicated for human immunodeficiency virus infection to alleviate viral load.
- Prescription status
POM
- Manufacturer
ViiV Healthcare
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store in the original container to protect from moisture.
- Drug interactions
metformin; antacids; calcium supplements
Precautions and warnings
monitor for hypersensitivity reactions; observe for signs of immune reconstitution syndrome; use with caution in hepatic impairment
Serious side effects
severe hypersensitivity reaction — requires immediate medical attention; suicidal ideation — requires immediate medical attention
Mechanism of action
This agent acts by inhibiting the strand transfer activity of the HIV integrase enzyme, a critical protein required for viral replication. By blocking the integration of the viral genome into host cell DNA, it suppresses viral proliferation.
Age restrictions
Applicable for use in children and adults depending on weight/age thresholds specified by the prescriber.
Pregnancy and breastfeeding
Pregnancy: Use may be considered after clinical evaluation. Breastfeeding: Not recommended due to potential transmission.
Tivicay
indicated for human immunodeficiency virus infection to alleviate viral load.
Editorial Notes
- Active ingredient(s): Dolutegravir
- Listed indication(s): HIV Infection
Available option
- 30 tablets - 50 mg1459-50-mg-17646